AstraZeneca lung cancer drug delays disease by more than a year

April 17, 2015 7:00 AM

3 0

LONDON, April 17 (Reuters) - An experimental lung cancer pill from AstraZeneca delays disease progression by more than a year, according to new data presented at a medical meeting on Friday.

AZD9291, which the company expects to file for U.S. approval in the second quarter of 2015, is one of a number of cancer medicines AstraZeneca is hoping will rebuild its sales following patent losses on older drugs.

Also read: LG Electronics says third-quarter profit down 3.7 percent vs. year earlier

Read more

To category page